Young Blood

As a business proposition, the transfusion of young blood raises all kinds of fears. It raises the spectre of a macabre black market, where teenagers bleed for the highest bidder, and young children go missing from the streets - Ian Sample

Young Blood

image by: Kunta Kinte

HWN Recommends

“Young Blood” Transfusions Are Not Ready For Primetime – Yet

Alzheimer's treatments have been famously difficult to develop; 99 percent of the 200-plus such clinical trials since 2000 have utterly failed. Even the few slight successes have failed to produce what is called 'disease modifying' agents that really help people with the disease. This makes the success, by the midsize Spanish pharma company Grifols, worthy of special attention.

However, the specifics of the Grifols treatment, a process called plasmapheresis, are atypical for another reason - they did not give patients a small molecule or an elaborate gene therapy, but rather simply the most common component of normal human blood plasma, a protein called albumin. A large portion of…

read full article


Related Articles

Stay Connected

©2021 | HealthWorldNet, Inc. | 115278

Last Updated : Tuesday, June 15, 2021